Consensus Recommendations for the Use of Automated Insulin Delivery Technologies in Clinical Practice
Open accessThe DOI matches its Crossref record; 144 of the 144 references it cites were found in a registry or an index.
Abstract
The significant and growing global prevalence of diabetes continues to challenge people with diabetes (PwD), healthcare providers, and payers. While maintaining near-normal glucose levels has been shown to prevent or delay the progression of the long-term complications of diabetes, a significant proportion of PwD are not attaining their glycemic goals. During the past 6 years, we have seen tremendous advances in automated insulin delivery (AID) technologies. Numerous randomized controlled trials and real-world studies have shown that the use of AID systems is safe and effective in helping PwD achieve their long-term glycemic goals while reducing hypoglycemia risk. Thus, AID systems have recently become an integral part of diabetes management. However, recommendations for using AID systems in clinical settings have been lacking. Such guided recommendations are critical for AID success and acceptance. All clinicians working with PwD need to become familiar with the available systems in order to eliminate disparities in diabetes quality of care. This report provides much-needed guidance for clinicians who are interested in utilizing AIDs and presents a comprehensive listing of the evidence payers should consider when determining eligibility criteria for AID insurance coverage.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Recent consensus recommendations suggest starting hypoglycemia treatment with 5 to 10 g of simple carbohydrates for automated insulin delivery systems where insulin pump algorithms integrate real-time data from continuous glucose monitors [28].”
From Systematic review of oral carbohydrate treatment for hypoglycemia in people living with type 2 diabetes mellitus (2026) · cites this paper as [28]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“There are separate consensus recommendations for people using automated insulin delivery who experience a hypoglycemia caused by exercise or excessive bolus of rapid-acting insulin [28].”
From Systematic review of oral carbohydrate treatment for hypoglycemia in people living with type 2 diabetes mellitus (2026) · cites this paper as [28]
The cited source says what the claim attributes to it.
In the citing paper
“By 2023, six out of these proposed algorithms advanced to systems accepted in the clinical practice: Medtronic 670G/770G, Medtronic 780G, CamAPS FX developed in Cambridge, UK, the French system Diabeloop, Tandem's Control-IQ, and Insulet's Omnipod 5. 112”
From Developing the UVA/Padova Type 1 Diabetes Simulator: Modeling, Validation, Refinements, and Utility (2023) · cites this paper as [112]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Battelino, T., Danne, T., Bergenstal, R. M., Amiel, S. A., Beck, R., Biester, T., Bosi, E., Buckingham, B. A., Cefalu, W. T., Close, K. L., et al. (2019) · Diabetes Care · doi:10.2337/dci19-0028 · Cited by 4,237
Self-citationInternational consensus on use of continuous glucose monitoring
Danne, T., Nimri, R., Battelino, T., Bergenstal, R. M., Close, K. L., DeVries, J. H., Garg, S., Heinemann, L., Hirsch, I., Amiel, S. A., et al. (2017) · Diabetes Care · doi:10.2337/dc17-1600 · Cited by 2,069
Self-citationState of Type 1 Diabetes Management and Outcomes from the T1D Exchange in 2016–2018
Foster, N. C., Beck, R. W., Miller, K. M., Clements, M. A., Rickels, M. R., DiMeglio, L. A., Maahs, D. M., Tamborlane, W. V., Bergenstal, R., Smith, E., et al. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0384 · Cited by 1,907
Self-citationUpdated Guidance on the Reporting of Race and Ethnicity in Medical and Science Journals
Flanagin, A., Frey, T., Christiansen, S. L., & AMA Manual of Style Committee (2021) · JAMA · doi:10.1001/jama.2021.13304 · Cited by 1,615
6. Glycemic Targets: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s006 · Cited by 1,403
Six-Month Randomized, Multicenter Trial of Closed-Loop Control in Type 1 Diabetes
Brown, S. A., Kovatchev, B. P., Raghinaru, D., Lum, J. W., Buckingham, B. A., Kudva, Y. C., Laffel, L. M., Levy, C. J., Pinsker, J. E., Wadwa, R. P., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1907863 · Cited by 1,030
Self-citationHolt, R. I. G., DeVries, J. H., Hess-Fischl, A., Hirsch, I. B., Kirkman, M. S., Klupa, T., Ludwig, B., Nørgaard, K., Pettus, J., Renard, E., et al. (2021) · Diabetes Care · doi:10.2337/dci21-0043 · Cited by 699
Self-citationSafety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes
Bergenstal, R. M., Garg, S., Weinzimer, S. A., Buckingham, B. A., Bode, B. W., Tamborlane, W. V., & Kaufman, F. R. (2016) · JAMA · doi:10.1001/jama.2016.11708 · Cited by 644
Self-citationGarg, S. K., Weinzimer, S. A., Tamborlane, W. V., Buckingham, B. A., Bode, B. W., Bailey, T. S., Brazg, R. L., Ilany, J., Slover, R. H., Anderson, S. M., et al. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2016.0421 · Cited by 585
Self-citation
Research works printed but not linked: 1
- 28. Ware J, Allen JM, Boughton CK, et al. Randomized trial of closedloop control in very young children with type 1 diabetes. N Engl J Med. 2022; 386 (3):209-219.
Cited by
Items 201–300 of 443
Closing in on closed-loop systems for type 2 diabetes
Beck, R. W. (2023) · Nature Medicine · doi:10.1038/s41591-022-02127-0 · Cited by 8
Self-citationDo-It-Yourself Automated Insulin Delivery: A Health-care Practitioner User’s Guide
Chambers, A., MacKay, D., Farnsworth, K., Morrison, A., Witteman, H. O., Senior, P. A., Halperin, I. J., BAJAJ, H. S., Barnes, T., Gilbert, J. D., et al. (2023) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2023.06.001 · Cited by 5
Demarcating the benefits of hybrid closed loop therapy in pregnant women with type 1 diabetes
Murphy, H. R., & SCOTT, E. M. (2024) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00104-9 · Cited by 5
Self-citationGómez, A. M., Henao, D. C., Múñoz, Ó., Romero-Alvernia, D. M., León, J. D. S., Jaramillo, P. E., Moscoso, E., Parra, D., Robledo, S., Maira, G., et al. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0589 · Cited by 5
The success of insulin pump therapy: importance of education of patients and health professionals
Carić, B., Marin, S., Pančić, J. M., Malešević, G., & Mirnić, D. (2024) · Frontiers in Clinical Diabetes and Healthcare · doi:10.3389/fcdhc.2024.1464365 · Cited by 7
Elbarbary, N. S., & Ismail, E. A. R. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112042 · Cited by 8
Continuous and Intermittent Glucose Monitoring in 2022
Dovč, K., Bode, B. W., & Battelino, T. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.2502 · Cited by 6
“…delivery, particularly with advanced hybrid closed-loop systems, became part of the standard recommendations from major professional associations (61); routine CGM usage is becoming recommended and reimbursed for individuals with insulin-treated diabetes, based on well-demonstrated bene-fits;…”
Self-citationMutlu, G. Y., Eviz, E., Can, E., Gökçe, T., Muradoğlu, S., & Hatun, Ş. (2023) · Clinical Diabetology · doi:10.5603/dk.a2022.0063 · Cited by 6
Medina, A. M. G., Henao, D. C., León, J. D. S., González, J. A. G., Múñoz, Ó., Brahim, L. C., Prada, G. A. M., & Rondón, M. (2023) · Journal of Diabetes Science and Technology · doi:10.1177/19322968231204376 · Cited by 7
Insights for personalized choice of a hybrid closed–loop system: an expert opinion
Molfetta, S. D., Boscari, F., Rossi, A., Girelli, A., Lepore, G., Bozzetto, L., Irace, C., Laviola, L., & Bruttomesso, D. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113120 · Cited by 4
Yang, Z., Chan, Y., Chan, D. S., Wu, C., Wang, Z., Jiang, Y., Liu, D., Xia, Z., Zhang, L., Cai, Y., et al. (2024) · Small Methods · doi:10.1002/smtd.202400159 · Cited by 4
Evolution of the Artificial Pancreas: Components and Integration—CGMs, Insulin, and AP Systems
Bergenstal, R. M., Heller, A., Breton, M. D., Vigersky, R. A., Brown, S. A., Forlenza, G. P., Sherr, J. L., Hovorka, R., Russell, S. J., Damiano, E. R., et al. (2025) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2025.18801.rmb · Cited by 6
“60 Generally, the AID systems employ various continuous glucose monitoring (CGM) sensors from Medtronic, Dexcom, and Abbott and use a variety of control algorithms, with PID (Proportional Integral Derivative) and MPC (Model Predictive Control) being most common.”
Self-citationReal-World Glycemic Improvements with Hybrid Closed Loop Pumps in Youth with Type 1 Diabetes
Rolón, M. E. D. V., Brown, E. A., & Wolf, R. M. (2023) · Pediatric Diabetes · doi:10.1155/2023/6621706 · Cited by 5
“Although diabetes technology use is associated with improved glycemic parameters, there is minimal representation of minority populations in CGM and pump trials, thereby limiting translatability of results to all individuals with diabetes [17, 18].”
Buckingham, B. A., & Bergenstal, R. M. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0505 · Cited by 6
Self-citationRoyston, C., Bergford, S., Calhoun, P. M., Sibayan, J., Ruan, Y., Boughton, C. K., Wilinska, M. E., & Hovorka, R. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2024.0298 · Cited by 4
Self-citationKietaibl, A.-T., Aziz, F., Wurm, E., Tomka, C., Moser, O., Pieber, T. R., Fröhlich-Reiterer, E. E., Fasching, P., Mader, J. K., Sourij, H., et al. (2024) · Biosensors · doi:10.3390/bios14090451 · Cited by 7
Szadkowska, A., Chobot, A. P., Głowińska‐Olszewska, B., Jarosz-Chobot, P. A., Mianowska, B., Myśliwiec, M., Szypowska, A., Zubkiewicz‐Kucharska, A., & Walczak, M. (2024) · Pediatric Endocrinology Diabetes and Metabolism · doi:10.5114/pedm.2024.144041 · Cited by 8
“Based on the available literature (mainly expert opinions [21]) it can be suggested that when using HCL systems during minor procedures, it may be beneficial to activate the Temporary Target function (in the MiniMed™ 780G system) or set a higher personal target glucose level, or use the “Ease-off”…”
BackgroundMethodInfluentialManaging diabetes across female reproductive stages
Mauricio, D., Gratacòs, M., & Franch‐Nadal, J. (2025) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2025.02.003 · Cited by 4
CHAWLA, P. M., Sowani, A., Parikh, R. M., Gupta, A. S., Kesavadev, J., Gokalani, R. A., Saboo, B., & Chawla, M. S. (2025) · Primary care diabetes · doi:10.1016/j.pcd.2025.06.004 · Cited by 4
Biester, T., Eckert, A. J., Becker, M., Boettcher, C., Golembowski, S., Heidtmann, B., Klinkert, C., Müther, S., Rami-Merhar, B. M., Holl, R. W., et al. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0283 · Cited by 4
“17 Therefore, when using AID systems, expected circadian profiles are still required as a basis for insulin pump settings at the start of therapy.”
Self-citationKubota, S., Sato, A., Hosokawa, M., Okubo, Y., Takayama, S., Kaneko, A., Shimada, Y., Asano, Y., Sato, Y., Yamazaki, M., et al. (2024) · Endocrine Journal · doi:10.1507/endocrj.ej24-0136 · Cited by 4
Sehgal, S., de Bock, M. I., Grosman, B., Williman, J. A., Kurtz, N., Guzman, V., Benedetti, A., Roy, A., Turksoy, K., Juarez, M., et al. (2024) · BMC Endocrine Disorders · doi:10.1186/s12902-024-01709-y · Cited by 4
Chen, J., Yu, K., Zhuang, S., & Zhang, D. (2024) · Frontiers in Neuroscience · doi:10.3389/fnins.2024.1342744 · Cited by 3
“The escalating prevalence of diabetes globally accentuates the critical need for effective management strategies, central to which is the monitoring of blood glucose levels (Phillip et al., 2023).”
BackgroundShapiro, J. B., Vesco, A. T., Carroll, M. S., & Weissberg-Benchell, J. A. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2024.0117 · Cited by 3
“Speci fi cally, three separate hierarchical regression analyses were conducted with different glycemic outcomes entered in Step 1 (baseline and change in [1] HbA1c, [2] TIR, [3] GRI) and AID-BBS bene-fi t and burden subscales entered in Step 2.”
Aktürk, H. K., Johnson, A. K., Welsh, J. B., & Messer, L. H. (2025) · Journal of Diabetes Science and Technology · doi:10.1177/19322968251330308 · Cited by 3
Self-citationWare, J., Bergford, S., Calhoun, P. M., Sibayan, J., Wilinska, M. E., Ruan, Y., & Hovorka, R. (2025) · Diabetes Technology & Therapeutics · doi:10.1177/15209156251376010 · Cited by 5
Self-citationDo, Q. D., Radovnická, L., Hašková, A., Konečná, J., Horová, E., Grunberger, G., Prázný, M., Parkin, C. G., Flekač, M., & Šoupal, J. (2025) · Diabetes Technology & Therapeutics · doi:10.1177/15209156251376013 · Cited by 3
“31,32 While signi fi cant variations among AID systems are typically not anticipated, 32 our study indicates that there might be differences that can be considered clinically relevant.”
Self-citationGioia, L. D., Molfetta, S. D., Caruso, I., Caporusso, M., Sorice, G. P., Cignarelli, A., Natalicchio, A., Perrini, S., Laviola, L., & Giorgino, F. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70176 · Cited by 3
Yılmaz, U. C., Demir, G., Kızılay, D. Ö., Özen, S., & Gökşen, D. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01800-0 · Cited by 4
“Early initiation of AID technologies may potentially support device acceptance among children and families, thereby enhancing treatment adherence [9] and may help reduce psychosocial stress in hypoglycemia management, which is critical for young patients coping with a T1D diagnosis [10, 11].”
A Pilot Outpatient Assessment of a Fully Closed-Loop Insulin and Pramlintide System
Odabassian, M., Tsoukas, M. A., Cohen, E., Pasqua, M., Rutkowski, J., & Haidar, A. (2025) · Journal of Diabetes Science and Technology · doi:10.1177/19322968251371046 · Cited by 3
“This decrease was primarily driven by reductions in bolus insulin (median 9–13 U) compared with the control intervention (18.5 [7.80-28”
InfluentialSelf-citationPasqua, M., Tsoukas, M. A., & Haidar, A. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70213 · Cited by 5
“17 This analysis aims to assess changes to insulin requirements over time with semaglutide use in T1D on pump therapy and how pump parameters may be affected.”
InfluentialSelf-citationRiveline, J., Renard, É., Aleppo, G., Bode, B. W., Brown, S. A., CASTORINO, K. N., Hirsch, I. B., Kipnes, M. S., Laffel, L. M., Lal, R., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70416 · Cited by 3
Self-citationStåhl, F. L., Hellman, J., & Ekelund, C. (2026) · Diabetes Technology & Therapeutics · doi:10.1177/15209156251414976 · Cited by 4
“4,29,30 The British National Institute for Health and Care Excellence recommends use for children and adolescents in gestational diabetes and for adults with HbA1c over 58 mmol/mol.”
Barash, G., Lerman, L., Ben‐Ari, T., Abiri, S., Landau, Z., Ami, M. B., Brener, A., Lebenthal, Y., Pinhas‐Hamiel, O., Mazor‐Aronovitch, K., et al. (2024) · Acta Diabetologica · doi:10.1007/s00592-024-02264-7 · Cited by 5
“Extended author information available on the last page of the article [1, 7, 8].”
BackgroundOser, C., Parascando, J. A., Kostiuk, M. A., Nagel, K. E., Oser, S. M., Huss, K. B., Westfeldt, E. B., Prince, B. K., & Oser, T. K. (2024) · Clinical Diabetes · doi:10.2337/cd24-0060 · Cited by 4
Self-citationSulik, B., Cook, K. P., & MacLeod, J. (2025) · Diabetes Technology and Obesity Medicine · doi:10.1089/dtom.2025.0010 · Cited by 3
“13 With advancing automation, the dietitian/diabetes care and education specialist (DCES) can shift from teaching advanced carbohydrate counting and math skills to true person-centered conversations focusing on healthy food choices including nutrient dense carbohydrates with adequate fi ber and…”
Wu, Z., Alexandre‐Heymann, L., Lebbar, M., Talbo, M. K., Bandini, A., Chahal, T., Grou, C., Messier, V., Boudreau, V., Brazeau, A., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70299 · Cited by 3
The Promise of Diabetes Technologies
Ebekozien, O. A., Hardison, H., & Shah, V. N. (2023) · Clinical Diabetology · doi:10.5603/dk.a2023.0001 · Cited by 3
Self-citationPros and cons of continous glucose monitoring
Ciechański, M., Witkowska, E., Ostańska, A., Szafran, A., Wiśniewska, K., Piasek, L., Godek, G., Więcław, K., Stańko, K., & Terelak, W. (2023) · Journal of Medical Science · doi:10.20883/medical.e873 · Cited by 4
Royston, C., Boughton, C. K., Nwokolo, M., Lakshman, R., Hartnell, S., Wilinska, M. E., Ware, J., Allen, J. M., Thabit, H., Mader, J. K., et al. (2024) · Journal of Diabetes Science and Technology · doi:10.1177/19322968241289963 · Cited by 4
Self-citationGlukosemessung und -kontrolle bei Patienten mit Typ-1- oder Typ-2-Diabetes
Schlüter, S., Deiss, D., Gehr, B., Lange, K., von Sengbusch, S., Thomas, A., Ziegler, R., Wiesner, T., & Freckmann, G. (2024) · Diabetologie und Stoffwechsel · doi:10.1055/a-2312-1073 · Cited by 3
McCarthy, O. M., Christensen, M. B., Tawfik, S., Kristensen, K. B., Hartmann, B., Holst, J. J., Schmidt, S., Nørgaard, K., & Bracken, R. M. (2024) · Nutrients · doi:10.3390/nu16234098 · Cited by 5
“…but simultaneously conducted and ongoing randomized, crossover trial exploring the e ffi cacy of the MiniMed 780G in people with elevated HbA 1c [18], during which trial the following eligibility criteria applied. were pregnant or breastfeeding; use of glucose-lowering medications (other than…”
Self-citationJames, S. G., Armstrong, M. E. G., Abdallah, Z. S., Emerson, H., & O’Kane, A. A. (2025) · CHI Conference on Human Factors in Computing Systems · doi:10.1145/3706598.3713247 · Cited by 6
“These systems will adjust the insulin delivery of the insulin pump based on glucose levels from a CGM without user input and have been found to improve glycaemic outcomes [12, 115].”
Glycemic variability and iatrogenic hypoglycemia: how to resolve
Monnier, L., Colette, C., Renard, É., Benhamou, P., Aouinti, S., Molinari, N., & Owens, D. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112360 · Cited by 3
Automated Insulin Delivery System and People With Type 2 Diabetes: A Topic With Many Facets
Heinemann, L. (2023) · Journal of Diabetes Science and Technology · doi:10.1177/19322968231204625 · Cited by 4
Self-citationMaia, A., Subías, D., Yuste, C., Albert, L., Vilaverde, J., Cardoso, M. H., & Rigla, M. (2024) · Journal of Diabetes Science and Technology · doi:10.1177/19322968241236456 · Cited by 2
“3,4 These systems employ sophisticated controller algorithms that continuously adjust insulin delivery in response to real-time sensor glucose levels, residual insulin action, and other factors, including meal intake and exercise announcements.”
Franceschi, R., Pertile, R., Marigliano, M., Mozzillo, E., Maffeis, C., Zaffani, S., Dusini, C., Antonelli, A., Maltoni, G., Candia, F. D., et al. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111962 · Cited by 2
Diabetes Without Math as Automation Advances: A Shifting Clinical Paradigm
Mora, P. A., Cook, K. P., & MacLeod, J. (2025) · Diabetes Technology and Obesity Medicine · doi:10.1089/dtom.2025.0033 · Cited by 3
“18 Clinical practice guidelines 19 and consensus recommendations on AID use in clinical practice 20 – 22 have been published.”
Sawyer, A., Forlenza, G. P., & Wadwa, R. P. (2025) · Expert Review of Medical Devices · doi:10.1080/17434440.2025.2585061 · Cited by 2
“While the uptake of AID has rapidly increased since its introduction, estimates suggest less than 50% of individuals with T1D in the U.S. and even less worldwide use AID systems despite their clear glycemic benefits [91,92].”
Self-citationShen, J., Zeng, T., Li, X., Zheng, C., Li, Y., Wu, X., Yao, H. J., Chen, L., Liu, Y., Zhu, W., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70227 · Cited by 3
Chahal, T., Alexandre‐Heymann, L., Yardley, J. E., Grou, C., Guédet, C. G., Messier, V., Boudreau, V., Courchesne, A., Brazeau, A., RABASA-LHORET, R. P. R., et al. (2025) · Diabetic Medicine · doi:10.1111/dme.70192 · Cited by 2
“8–10 AID integrates a continuous glucose monitor (CGM), an insulin pump and an algorithm that automatically adjusts insulin delivery to maintain blood glucose levels.”
Zhou, Y., LEI, M., Lin, Q., NI, Y., Lin, Z., Yang, D., Wang, C., Xu, W., & Yan, J. (2026) · Diabetes Technology & Therapeutics · doi:10.1177/15209156261420209 · Cited by 2
Bruttomesso, D., Petrie, J. R., Evans, M. L., Fleming, G. A., Hanaire, H. P., Holl, R. W., Sherr, J. L., Bergenstal, R. M., Heinemann, L., & Peters, A. L. (2026) · Diabetologia · doi:10.1007/s00125-025-06651-9 · Cited by 3
Self-citationWarunyuwong, W., Boucsein, A., Sneddon, K. M. B., de Ribot, F. M., Sime, M.-J., Zhou, Y., Wilkinson, T., de Bock, M. I., Wiltshire, E. J., Paul, R. G., et al. (2026) · Journal of Diabetes Science and Technology · doi:10.1177/19322968261446654 · Cited by 2
Schumacher, C., Tsoukas, M. A., Legault, L., Pasqua, M., Kemp, G., Cohen, E., Jones, R., Dassau, E., & Haidar, A. (2026) · Diabetes Technology & Therapeutics · doi:10.1177/15209156261456440 · Cited by 2
Self-citationSawyer, A., Wilmot, E. G., Do, D., Miller, K. M., Ly, T. T., & Forlenza, G. P. (2026) · Diabetes Technology & Therapeutics · doi:10.1177/15209156261456826 · Cited by 3
“12 For Medtronic AID systems, it is suggested to strengthen I:C ratios by 10% and select an active insulin time of 2 – 4 h.”
Self-citationMcGill, J. B., Donihi, A. C., Aktürk, H. K., Freeby, M., Gupta, A., Horton, W. B., Jadoon, M. N., Lathief, S., Miracle-López, S., Tan, C., et al. (2026) · Endocrine Practice · doi:10.1016/j.eprac.2026.06.011 · Cited by 3
Altınok, Y. A., Mansuroglu, Y., Demir, G., Balkı, H. G., Özen, S., Darcan, Ş., & Gökşen, D. (2024) · European Journal of Clinical Nutrition · doi:10.1038/s41430-024-01422-y · Cited by 3
“However, despite signi fi - cant advances in controller algorithms in providing closed-loop insulin delivery between meals, users must still manually announce carbohydrate intake to achieve adequate postprandial insulin coverage [1].”
BackgroundMartín‐Payo, R., Fernandez-Alvarez, M. D. M., García-García, R., Pérez-Varela, Á., Surendran, S., & Galán, I. R. (2024) · Anales de Pediatría (English Edition) · doi:10.1016/j.anpede.2024.07.015 · Cited by 2
“Larger, multicentre studies with hybrid closed-loop systems would allow comparisons based on the type of physical activity performed and would open exciting new avenues for future research.”
Beyond the insulin pump: Unraveling diabetes tech dependency
Feliziani, E., Chios, M. C., & Pozzilli, P. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111896 · Cited by 2
Nitschke, M. J., Hemmingsen, M. H., Nørgaard, H., Robak, K. A., Nørrevang, P., Meldgaard, M., Dejgaard, T. F., Pedersen‐Bjergaard, U., & Kristensen, P. L. (2025) · Journal of Diabetes Science and Technology · doi:10.1177/19322968251315184 · Cited by 2
Ethical Issues in Pediatric Endocrinology
Ladd, J. M., & Henry, R. K. (2025) · Advances in Pediatrics · doi:10.1016/j.yapd.2024.12.002 · Cited by 2
Papa, G. F. S., Cannarella, R., Finocchiaro, C., Anzaldi, M., Gruttadauria, G., Presti, D. L., Condorelli, R. A., Vignera, S. L., & Calogero, A. E. (2025) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2025.108984 · Cited by 2
Henske, J. A., Turner, L. V., & Riddell, M. C. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf136 · Cited by 2
Self-citationNavigating Automated Insulin Delivery for Type 1 Diabetes Management During Pregnancy
Scifres, C., Cleary, E. M., Sheerer, M., Bowdler, M., & Shah, V. N. (2025) · Journal of Diabetes Science and Technology · doi:10.1177/19322968251334597 · Cited by 3
“13,14,16,18,19 A recent review of clinical trials and real-world studies in non-pregnant populations using HCL therapy found that the TIR improved by 5% to 10% with HCL therapy across studies, and the TIR was 70% to 75% for most systems.”
Self-citationMarshall, A., Lim, L., Allyson, M., Youde, L. S., Nillsen, A., Bui, N. H., Townsend, N., Monique, S., Wanaguru, A., Ramjan, K. A., et al. (2023) · Journal of Paediatrics and Child Health · doi:10.1111/jpc.16493 · Cited by 2
Datye, K. A., Bonnet, K. R., Parmar, A. M., Schlundt, D. G., & Jaser, S. S. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2024.0210 · Cited by 1
Innovation is the driver behind quality improvements in diabetes care delivery
Hirsch, I. B., & Parkin, C. G. (2024) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2024.30.10-b.s2 · Cited by 1
Self-citation100 Years of Insulin: A Historical Perspective
Pinto, G. B., Itabaiana, I., de Magalhães, J. L., & Antunes, A. M. D. S. (2025) · Current Topics in Medicinal Chemistry · doi:10.2174/0115680266315941241127092613 · Cited by 1
Aboznadah, W. M., Tsoukas, M. A., Hu, X., & Pasqua, M. (2025) · JCEM Case Reports · doi:10.1210/jcemcr/luaf021 · Cited by 1
“Because of the reduction in hypoglycemia and impact on quality of life [21, 22], systematically removing automation postbariatric surgery is not recommended.”
Zahradnická, M., Németová, L., Kahle, M., Vávra, D., Bém, R., Girman, P., Haluzík, M., & Saudek, F. (2025) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2024.0606 · Cited by 1
“13 In the present study, we aimed to compare metabolic parameters between patients using state-of-the-art AID technology, versus those who had undergone SPK transplantation.”
Manos, G., Apostolopoulos, J., Read, M., Cox, M., Gao, F. M., Henshaw, K., Hines, C., Jenkins, A. J., Kiburg, K., Pham, C. T., et al. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112171 · Cited by 7
Self-citationFushimi, E., Bianchi, F. D., Battista, H. D., & Garelli, F. (2025) · Journal of Applied Biomedicine · doi:10.1016/j.bbe.2025.05.004 · Cited by 1
Supported Open-Source Automated Insulin Delivery for Management of Type 1 Diabetes in Pregnancy
Hawke, K., Kabootari, M., & Elliott, T. (2025) · Journal of Diabetes Science and Technology · doi:10.1177/19322968251336779 · Cited by 1
Echevarría, M. C., Evans, R. E., & Schmitt, J. A. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1568133 · Cited by 2
“Therefore, CSII should be considered a viable treatment option for pediatric patients with diabetes, particularly those with suboptimal glycemic control, as it has the potential to improve both therapeutic ef fi cacy and overall safety in this population (11, 12).”
Artificial Pancreas: The First 20 Years
Doyle, F. J., & Kovatchev, B. P. (2025) · Journal of Diabetes Science and Technology · doi:10.1177/19322968251330920 · Cited by 5
“90-92 Overall, while detailed comparisons of results across studies are not statistically plausible due to differences in sensors used, experimental setup, and lack of randomization, it became evident that (1) all contemporary AP systems perform significantly better than both multiple daily…”
Self-citationRateb, R. M., Salah, A., Kertam, A., Ashmawi, Y. A. Y., Mahmoud, N. H., Afifi, E., Bayoumi, A., Allam, S., & Rakab, M. S. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01906-2 · Cited by 1
“There was no significant reduction in total daily insulin intake; this can be attributed to the manual calculation of the meal bolus and user glycemic control variability with the primary goal of maintaining the patient in an euglyce-mic state [34].”
Gea, I. L., Jabato, F. M., Jiménez, A. B. A., Jurado, A. L., Gómez‐Perea, A., Romero-Pérez, M. D. M., García, E. G., Mata, M. Á. S., Martínez-Moya, G., Momblán, J. J., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14176243 · Cited by 2
“This paper gains vital importance at the current moment, when multiple guidelines position closed-loop therapy as the first indication in pediatric patients with T1D, necessitating tools for scalability planning and outcome evaluation [29–31].”
Taylor, G., Burger, B., Scragg, J. H., Page, O. L., Schmid, H., Nsengimana, J., West, D. J., & Shaw, J. (2025) · Diabetes Technology & Therapeutics · doi:10.1177/15209156251370942 · Cited by 1
“18 Our data are in keeping with previous studies reporting substantially more TIR and less TAR overall and while sleeping in people using HCL systems in comparison to unlinked CSII or MDI.”
Lawton, J., Kyle, C. J., Chambers, T. J. G., Steven, L., Currie, A., Gibb, F. W., McKnight, J. A., & Rankin, D. (2025) · Diabetic Medicine · doi:10.1111/dme.70153 · Cited by 1
“2,21 In keeping with our interviewees' suggestions, this kind of support could be provided remotely (e.g., via video-conferencing), reducing the need for in-person visits.”
Self-citationPasqua, M., Doumat, J., Tsoukas, M. A., & Haidar, A. (2025) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2025.10.175 · Cited by 1
Self-citationPilot Study of Early Adoption of Automated Insulin Delivery in Underresourced Youth
Yen, K., Belapurkar, S., Puckett, C., Chen, N. S., YGLECIAS, L., Bal, K., Hickey, J., CARELLI, L. L., LOUCEL, C. M., Lodish, M. B., et al. (2025) · Journal of Diabetes Research · doi:10.1155/jdr/6886806 · Cited by 5
“Diabetes technology has advanced signi fi cantly since the fi rst commercially available automated insulin delivery (AID) system was approved in 2016 [1].”
Automated Insulin Delivery Beyond Glycemic Outcomes: Endpoints and Evidence
Jones, H. C., Trawley, S. L., Jenkins, A. J., MacIsaac, R. J., Kong, Y. W., Morrison, D., & O'Neal, D. N. (2025) · Diabetes Technology & Therapeutics · doi:10.1177/15209156251390831 · Cited by 3
“123 For individuals with diabetes, AID systems depend on continuous insulin delivery, accurate glucose monitoring, and seamless algorithmic control to prevent medical emergencies such as diabetic ketoacidosis (DKA) or severe hypoglycemia.”
Self-citationAngelino, S., Maiorino, M. I., Petrizzo, M., Martino, N. D., Caruso, P., Carbone, C., Pontillo, A., Maio, A., Longo, M., Scappaticcio, L., et al. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1717249 · Cited by 1
Glukosemessung und -kontrolle bei Patienten mit Typ-1- oder Typ-2-Diabetes
Schlüter, S., Deiss, D., Gehr, B., Lange, K., von Sengbusch, S., Thomas, A., Ziegler, R., Wiesner, T., & Freckmann, G. (2025) · Diabetologie und Stoffwechsel · doi:10.1055/a-2592-7783 · Cited by 3
Kadiyala, N., Allen, J., Lakshman, R., Boughton, C. K., Wilinska, M. E., Thankamony, A., Hartnell, S., Thabit, H., Willemsen, R. H., Shah, P., et al. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.113078 · Cited by 1
Self-citationInsulin Pump Guide for Health Care Professionals: Settings, Interpretation, and Adjustment
Lansang, M. C., Malloy, K., Knapp, S., Veeramachaneni, R., Rahhal, M.-N., Arce, K. M., Mucci, A., Zhou, K., & Isaacs, D. M. (2026) · Endocrine Practice · doi:10.1016/j.eprac.2025.12.025 · Cited by 1
Self-citationPavlou, P., Leelarathna, L., Avari, P., Hussain, S., Johnston, T., Hyslop, R., Pender, S., & Karalliedde, J. J. (2026) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2026.2619097 · Cited by 2
“In contrast, automated insulin delivery systems (AID) integrate insulin pumps with continuous glucose monitoring (CGM) devices using mathematical algorithms, allowing for glucose-responsive insulin delivery [30].”
Self-citationTiming of insulin pump initiation among individuals with type 1 diabetes in Ontario, Canada
Zhu, X., Lipscombe, L. L., Shulman, R. M., Lovblom, L. E., Everett, K., & Weisman, A. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70514 · Cited by 1
Valdez, Y., Parimi, N., Kim, Y. C., Brown, E. A., Sidhaye, A. R., Wolf, R. M., & Mathioudakis, N. N. (2026) · Journal of Diabetes Science and Technology · doi:10.1177/19322968261417375 · Cited by 1
Šantová, A., Plachý, L., Neuman, V., Amaratunga, S. A., Slavenko, M. G., Obermannová, B., Drnkova, L., Průhová, Š., & Šumník, Z. (2026) · Diabetes Technology & Therapeutics · doi:10.1177/15209156251415187 · Cited by 1
“1,19 The methodology and protocol of our study unfortunately do not allow us to determine unequivocally the relative contribution of each algorithmic feature; however, the outcomes of systems that implement automated correction boluses — including do-it-yourself closed-loop con fi gurations 20 — may…”
Ein Kommentar der AGDT zu smarten Insulinpen-Therapiesystemen
Schlüter, S., Freckmann, G., & Lange, K. (2026) · Die Diabetologie · doi:10.1007/s11428-026-01436-z · Cited by 1
Rodbard, D., Augstein, P., Heinke, P., Salzsieder, E., Thomas, A., & Reindel, J. (2026) · Diabetes Technology & Therapeutics · doi:10.1177/15209156261423504 · Cited by 1
Self-citationMoser, O., Becker, U., van den Boom, L., Brinkmann, C. K., Danne, T., Fröhlich-Reiterer, E. E., Gehr, B., Kietaibl, A.-T., Köhler, G., Kreß, S., et al. (2026) · Wiener klinische Wochenschrift · doi:10.1007/s00508-025-02663-y · Cited by 1
Self-citationLindkvist, E. B., McCarthy, O. M., Tawfik, S., Sørensen, M. Z., Bracken, R. M., Ranjan, A. G., Svensson, J., & Nørgaard, K. (2026) · Diabetes Technology & Therapeutics · doi:10.1177/15209156261456820 · Cited by 1
“Additionally, there were no differences in the amount of insulin delivered (total insulin dose; HIIE: 27.3 [23.4 – 32.8] IU vs. MICE: 28.8 [21.2 – 32.2] IU, P = 0.147) nor the amount of carbohydrates announced to the AID systems.”
InfluentialSelf-citationAnson, M., Iqbal, A., Azmi, S., Weston, P. J., Hughes, L., Choudhury, M., Hughes, D. M., Zheng, Y., Burgess, P. I., & Alam, U. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71084 · Cited by 1
Ayhan, D. B., & Özdemir, S. (2026) · Journal of Pediatric Nursing · doi:10.1016/j.pedn.2026.08.011 · Cited by 1
Joubert, M., Amouyal, C., Bismuth, É., Borot, S., Hanaire, H. P., Lablanche, S., Penfornis, A., Perge, K., Schaepelynck, P., & Vaduva, P. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71369 · Cited by 1
Müller-Korbsch, M., Kietaibl, A.-T., Haufe, Y., & Fasching, P. (2023) · Diabetes Epidemiology and Management · doi:10.1016/j.deman.2023.100150 · Cited by 1
Serafini, M. C., Rosales, N., & Garelli, F. (2023) · Computer Methods in Biomechanics & Biomedical Engineering · doi:10.1080/10255842.2023.2241945 · Cited by 2
“For all strategies, acceptable times outside of normoglycemia were chosen based on recent consensus (Phillip et al. 2022).”
Metadata
- Authors
- Phillip, M., Nimri, R., Bergenstal, R. M., Barnard-Kelly, K., Danne, T., Hovorka, R., Kovatchev, B. P., Messer, L. H., Parkin, C. G., Ambler-Osborn, L., Amiel, S. A., Bally, L., Beck, R. W., Biester, S., Biester, T., Blanchette, J. E., Bosi, E., Boughton, C. K., Breton, M. D., Brown, S. A., Buckingham, B. A., Cai, A., Carlson, A. L., Castle, J. R., Choudhary, P., Close, K. L., Cobelli, C., Criego, A. B., Davis, E., de Beaufort, C., de Bock, M. I., DeSalvo, D. J., DeVries, J. H., Dovc, K., Doyle, F. J., Ekhlaspour, L., Shvalb, N. F., Forlenza, G. P., Gallen, G., Garg, S. K., Gershenoff, D. C., Gonder-Frederick, L. A., Haidar, A., Hartnell, S., Heinemann, L., Heller, S., Hirsch, I. B., Hood, K. K., Isaacs, D., Klonoff, D. C., Kordonouri, O., Kowalski, A., Laffel, L., Lawton, J., Lal, R. A., Leelarathna, L., Maahs, D. M., Murphy, H. R., Nørgaard, K., O’Neal, D., Oser, S., Oser, T., Renard, E., Riddell, M. C., Rodbard, D., Russell, S. J., Schatz, D. A., Shah, V. N., Sherr, J. L., Simonson, G. D., Wadwa, R. P., Ward, C., Weinzimer, S. A., Wilmot, E. G., & Battelino, T.
- Affiliations
- Tel Aviv University (IL)
- HealthPartners (US)
- Southern Health NHS Foundation Trust (GB)
- Kinderkrankenhaus auf der Bult (DE)
- University of Cambridge (GB)
- University of Virginia (US)
- University of Colorado Anschutz (US)
- CGParkin Communications, Inc. , Henderson, NV , USA
- Joslin Diabetes Center (US)
- King's College London (GB)
- University of Bern (CH)
- Jaeb Center for Health Research (US)
- University of Utah (US)
- Vita-Salute San Raffaele University (IT)
- Stanford Medicine (US)
- Close Concerns (United States) (US)
- Oregon Health & Science University (US)
- University of Leicester (GB)
- University of Padua (IT)
- The Kids Research Institute Australia (AU)
- Diabetes & Endocrine Care Clinique Pédiatrique DECCP/Centre Hospitalier Luxembourg, and Faculty of Sciences, Technology and Medicine, University of Luxembourg, Esch sur Alzette, GD Luxembourg/Department of Paediatrics, UZ-VUB , Brussels , Belgium
- Department of Paediatrics, University of Otago , Christchurch , New Zealand
- Baylor College of Medicine (US)
- Amsterdam University Medical Centers (NL)
- Department of Pediatric Endocrinology, Diabetes and Metabolic Diseases, UMC - University Children’s Hospital, Ljubljana, Slovenia, and Faculty of Medicine, University of Ljubljana , Ljubljana , Slovenia
- Harvard University (US)
- Lucile Packard Children's Hospital (US)
- The Jesse Z and Sara Lea Shafer Institute for Endocrinology and Diabetes, National Center for Childhood Diabetes, Schneider Children’s Medical Center of Israel , 49202 Petah Tikva , Israel
- McGill University (CA)
- Cambridge University Hospitals NHS Foundation Trust (GB)
- Science Consulting in Diabetes GmbH , Kaarst , Germany
- University of Sheffield (GB)
- University of Washington (US)
- Cleveland Clinic (US)
- Diabetes Research Institute, Mills-Peninsula Medical Center , San Mateo, CA 94010 , USA
- Breakthrough T1D (US)
- University of Edinburgh (GB)
- University of Manchester (GB)
- University of East Anglia (GB)
- University of Copenhagen (DK)
- Department of Medicine and Department of Endocrinology, St Vincent’s Hospital Melbourne, University of Melbourne , Melbourne , Australia
- Department of Endocrinology, Diabetes, Nutrition, Montpellier University Hospital, and Institute of Functional Genomics, University of Montpellier, CNRS, INSERM , Montpellier , France
- York University (CA)
- Biomedical Informatics Consultants LLC , Potomac, MD , USA
- University of Florida (US)
- Yale University (US)
- University of Nottingham (GB)
- University of Ljubljana (SI)
- Corresponding author
- Phillip, Moshe
- Nimri, Revital
- ORCID
- Phillip, Moshe
- Nimri, Revital
- Bergenstal, Richard M
- Barnard-Kelly, Katharine
- Danne, Thomas
- Hovorka, Roman
- Kovatchev, Boris P
- Messer, Laurel H
- Parkin, Christopher G
- Amiel, Stephanie A
- Bally, Lia
- Beck, Roy W
- Biester, Torben
- Blanchette, Julia E
- Bosi, Emanuele
- Boughton, Charlotte K
- Breton, Marc D
- Brown, Sue A
- Buckingham, Bruce A
- Carlson, Anders L
- Castle, Jessica R
- Choudhary, Pratik
- Close, Kelly L
- Cobelli, Claudio
- Criego, Amy B
- Davis, Elizabeth
- de Beaufort, Carine
- de Bock, Martin I
- DeSalvo, Daniel J
- DeVries, J Hans
- Dovc, Klemen
- Doyle, Francis J
- Ekhlaspour, Laya
- Shvalb, Naama Fisch
- Forlenza, Gregory P
- Gallen, Geraldine
- Garg, Satish K
- Gonder-Frederick, Linda A
- Haidar, Ahmad
- Hartnell, Sara
- Heinemann, Lutz
- Heller, Simon
- Hirsch, Irl B
- Hood, Korey K
- Isaacs, Diana
- Klonoff, David C
- Kordonouri, Olga
- Kowalski, Aaron
- Laffel, Lori
- Lawton, Julia
- Lal, Rayhan A
- Leelarathna, Lalantha
- Maahs, David M
- Murphy, Helen R
- Nørgaard, Kirsten
- Oser, Sean
- Oser, Tamara
- Renard, Eric
- Riddell, Michael C
- Rodbard, David
- Russell, Steven J
- Schatz, Desmond A
- Shah, Viral N
- Sherr, Jennifer L
- Simonson, Gregg D
- Wadwa, R Paul
- Weinzimer, Stuart A
- Wilmot, Emma G
- Battelino, Tadej
- Venue
- Endocrine Reviews
- Publisher
- The Endocrine Society
- Published
- 2022-09-06
- Volume
- 44
- Issue
- 2
- Pages
- 254-280
- ISSN
- 0163-769X (ISSN-L)
- 1945-7189
- PMC
- PMC9985411
- OpenAlex
- W4294783598
- Semantic Scholar
- 28646f57b5b3cbcfac8f10ea51308aadbf9e4f00
- Cited by
- 443
- References
- 144
- Citations by year
- 2026: 102 · 2025: 121 · 2024: 141 · 2023: 76 · 2022: 3
- FWCI
- 63.20
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Endocrine Reviews (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Repository@Nottingham (University of Nottingham) (publishedVersion, cc-by-nc-nd)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, cc-by-nc-nd)
- White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (acceptedVersion)
- Pure Amsterdam UMC (acceptedVersion, cc-by)
- HAL (submittedVersion, cc-by-nc-nd)
- Repository@Nottingham (University of Nottingham) (submittedVersion, cc-by-nc-nd)
- Digital Commons-TMC (Texas Medical Center) (submittedVersion)
- UWA Profiles and Research Repository (UWA) (submittedVersion, cc-by-nc-nd)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Bern Open Repository and Information System (University of Bern) (submittedVersion, cc-by-nc-nd)
- Figshare (submittedVersion, cc-by-nc-nd)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- Edinburgh Research Explorer (University of Edinburgh) (submittedVersion, cc-by)
- Open Access CRIS of the University of Bern
- Funders
- Amgen
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Sanofi
- Leona M. and Harry B. Helmsley Charitable Trust
- University of Virginia
- Bigfoot Biomedical
- Insulet Corporation
- MannKind Corporation
- Dexcom
- Steno Diabetes Center Copenhagen (SDCC 3.E Technology)
- Cardinal Health
- Tandem Diabetes Care
- National Institute for Health and Care Research (16/35/01, CL-2020-14-801)
- Novo Nordisk
- Roche Diabetes Care
- National Institutes of Health (UL1TR001863)
- University of Colorado Denver
- Abbott Diabetes Care
- National Institute of Diabetes and Digestive and Kidney Diseases (K23DK121942, K23DK122017, R01DK129553, P30DK045735)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- artificial pancreas, diabetes management, glycemic control, hypoglycemia risk, insulin pump therapy, continuous glucose monitoring, eligibility criteria, clinical guidelines
- MeSH terms
- Blood Glucose, Diabetes Mellitus, Type 1, Humans, Hypoglycemic Agents, Insulin, Blood Glucose Self-Monitoring, Consensus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.